|
시장보고서
상품코드
2075811
기관지 확장제 시장 : 약제 클래스별, 투여 경로별, 적응증별, 유통 채널별, 지역별Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 기관지 확장제 시장은 2026년에 237억 8,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 313억 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 4.0%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 237억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 4.00% | 시장 규모 예측(2033년) : | 313억 달러 |
기관지 확장제는 폐의 기도를 넓혀 호흡을 편하게 해주는 약입니다. 기관지를 둘러싼 평활근을 이완 및 확장시켜 작용하며, 천식이나 만성 폐쇄성 폐질환(COPD) 등의 호흡기 질환에 수반되는 천명음, 기침, 호흡곤란 등의 증상을 완화합니다. 기관지 확장제에는 갑작스럽고 예기치 못한 호흡곤란 발작을 단기적으로 완화하기 위해 사용되는 '단시간 작용형'과, 천식이나 COPD에서 호흡곤란을 조절하고, 천식에서 코르티코스테로이드의 효과를 높이기 위해 정기적으로 사용되는 '장시간 작용형'이 있습니다. 항콜린제(항무스카린제라고도 함)는 주로 만성 폐쇄성 폐질환(COPD) 치료에 사용되지만, 일부는 천식 치료에도 사용될 수 있습니다. 항콜린제는 콜린성 신경을 차단함으로써 기도를 확장시킵니다. 기관지 확장제의 부작용은 구체적인 약제에 따라 다릅니다. 일반적인 부작용으로는 특히 손 떨림, 두통, 근육 경련, 메스꺼움이나 구토, 설사 등이 있습니다.
시장 역학 :
세계의 기관지 확장제 시장의 성장은 호흡기 질환에 걸리기 쉬운 고령 인구 증가, 도시 및 농촌 지역의 환경 오염 수준 악화, 천식 및 만성 폐쇄성 폐질환(COPD)에 대한 적절한 관리에 대한 인식 제고와 같은 요인들에 의해 주도되고 있습니다. 그러나 대체 치료법의 존재, 기관지 확장제의 장기 사용에 따른 부작용, 그리고 블록버스터 의약품의 특허 만료 등은 시장 성장을 저해할 것으로 예상되는 주요 요인 중 일부입니다. 2유형 이상의 약제를 동시에 투여할 수 있는 병용 요법의 개발은 이 시장의 참여자들에게 새로운 기회를 제공합니다. 또한, 호흡기 증상을 보다 적절하게 관리하기 위한 예방적 흡입 요법에 대한 관심이 높아짐에 따라 향후 수요가 증가할 것으로 보입니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 기관지 확장제 시장의 주요 기업 프로파일을 작성하고 있습니다. 본 조사에서 다루고 있는 주요 기업으로는 GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi 및 Innoviva가 있습니다.
- 본 보고서에서 얻을 수 있는 인사이트은 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내리는 데 도움이 됩니다.
- 이 책 '세계의 기관지 확장제 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 기관지 확장제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 기관지 확장제 시장 : 약제 클래스별(2021-2033년)
제5장 세계의 기관지 확장제 시장 : 투여 경로별(2021-2033년)
제6장 세계의 기관지 확장제 시장 : 적응증별(2021-2033년)
제7장 세계의 기관지 확장제 시장 : 유통 채널별(2021-2033년)
제8장 세계의 기관지 확장제 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
AJY 26.07.09Global Bronchodilators Market is estimated to be valued at USD 23.78 Bn in 2026 and is expected to reach USD 31.30 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 23.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.00% | 2033 Value Projection: | USD 31.30 Bn |
Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.
Market Dynamics:
The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market
Detailed Segmentation:
- Global Bronchodilators Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Beta-adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Global Bronchodilators Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Nasal (inhalable)
- Injectable
- Global Bronchodilators Market, By Indication (Revenue, USD Bn, 2021 - 2033)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others (Chronic bronchitis, etc.)
- Global Bronchodilators Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Global Bronchodilators Market:
- GSK plc.
- AbbVie Inc.
- AstraZeneca
- Mylan N.V.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Product Approval
- Stringent Regulatory Environment
- Increasing Awareness Campaigns
- Key Highlights
- Regulatory Scenario
- Market Trends
- Pipeline Analysis
- Product Launch/Approval
- PEST Analysis
- PORTER's Analysis
- Epidemiology
- Treatment Algorithm (Patient Journey)
- Treatment Option Analysis
- New Investments by Major Market Players
- Pricing Analysis
- Disease Awareness Programs
- Treatment Safety and Efficacy Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bronchodilators Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Beta-adrenergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Xanthine Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Anticholinergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
5. Global Bronchodilators Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Nasal (inhalable)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
6. Global Bronchodilators Market, By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others (Chronic bronchitis, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Bronchodilators Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 201s9-2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
8. Global Bronchodilators Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Innoviva
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc.
- Analyst Views
10. Section
- References
- Research Methodology
- About us
